Abstract
Aim: To estimate the comparative efficacy of cemiplimab, a programmed cell death protein 1 inhibitor, versus EGFR inhibitors, pembrolizumab and platinum-based chemotherapy in terms of overall survival (OS) and progression-free survival. Patients & methods: We performed an indirect treatment comparison of cemiplimab and other available systemic therapies for patients with advanced cutaneous squamous cell carcinoma. Results: Cemiplimab was associated with benefits in OS (hazard ratios range: 0.07-0.52) and progression-free survival (hazard ratios range: 0.30-0.67) versus EGFR inhibitors and pembrolizumab (data from KEYNOTE-629). Cemiplimab was more efficacious versus platinum-based chemotherapy in terms of OS. Conclusion: Cemiplimab may offer improvements in survival for advanced cutaneous squamous cell carcinoma patients compared with existing systemic therapies.
Keywords:
cemiplimab; cutaneous squamous cell carcinoma; immuno-oncology; indirect treatment comparison; nonmelanoma skin cancer.
Publication types
-
Comparative Study
-
Systematic Review
MeSH terms
-
Antibodies, Monoclonal, Humanized / pharmacology
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carboplatin / pharmacology
-
Carcinoma, Squamous Cell / drug therapy*
-
Carcinoma, Squamous Cell / immunology
-
Carcinoma, Squamous Cell / mortality
-
Carcinoma, Squamous Cell / pathology
-
Cetuximab / pharmacology
-
Cetuximab / therapeutic use
-
Cisplatin / pharmacology
-
Cisplatin / therapeutic use
-
Clinical Trials as Topic
-
ErbB Receptors / antagonists & inhibitors
-
Humans
-
Immune Checkpoint Inhibitors / pharmacology
-
Immune Checkpoint Inhibitors / therapeutic use*
-
Observational Studies as Topic
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors
-
Programmed Cell Death 1 Receptor / metabolism
-
Progression-Free Survival
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / immunology
-
Skin Neoplasms / mortality
-
Skin Neoplasms / pathology
Substances
-
Antibodies, Monoclonal, Humanized
-
Immune Checkpoint Inhibitors
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor
-
cemiplimab
-
Carboplatin
-
pembrolizumab
-
EGFR protein, human
-
ErbB Receptors
-
Cetuximab
-
Cisplatin